Recent advances in technology allow us to consider the epigenome as well as the genome of a tumour on an individual level. These advances, in combination with high throughput technologies, are leading to rapid advances in the development of epigenetic biomarkers and novel therapeutic targets.
Epigenetic pathways are frequently perturbed in cancer cells, highlighting the central role that epigenetic changes play in the process of tumourigenesis. Understanding how these changes lead to cancer progression at a molecular level is a key component to translating epigenetics into the clinic.
